Ebola vaccine trials in Guinea since March 2015 have been a complete success. The drug, tentatively titled rVSV-ZEBOV, was developed by the Canadian Public Health Agency with financial support from the US and Canadian governments. Professor Donald Henderson of Johns Hopkins University, known for developing a circular vaccination strategy to eradicate smallpox, was invaluable in research assistance.
The obtained positive results of the effectiveness and safety of the vaccine make it possible to recommend its use for children from 13-17 years old, and possibly from 6-12 years old. Clinical trials were carried out in 90 foci of the disease. In 48 of them, vaccination was carried out immediately after the diagnosis of fever, and in 42 - after 21 days. In the first group, no one got sick, and in the second, 16 people were diagnosed with fever. A total of 7651 people voluntarily participated in the testing.
At this stage, the World Health Organization plans to use the vaccine to eliminate foci of infection, and not for preventive vaccinations. The caution in use is due to the fact that there was no placebo effect during the trials, which could slightly overestimate the effectiveness of rVSV-ZEBOV.